Clinical Trial Update: Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anlotinib plus penpulimab in advanced non-small cell lung cancer after prior PD-1/PD-L1 inhibitor treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Penpulimab

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN